Innovital Systems Inc.

Innovital Systems Inc. is a small, for-profit advanced technology company headquartered in Calverton, Maryland, and registered in SAM.gov since March 2013. The company specializes in biomedical engineering, product development, and research services for federal agencies, with a particular focus on defense-related innovations in medical devices, survivability engineering, and sensor technologies. Innovital has established itself as a reliable partner to the Department of Defense and other federal agencies through its expertise in developing cutting-edge solutions for battlefield and emergency medical care applications.

Through its prime federal contracts, Innovital has demonstrated substantial capability in delivering specialized medical devices and engineering solutions. The company has received multiple Small Business Innovation Research (SBIR) Phase II definitive contracts totaling approximately $5.9 million, including awards from the Defense Health Agency for development of a junctional tourniquet ($1.299 million), an antiseptic and warming casualty transport pad ($1.3 million), and the CLR device for managing hemothorax ($1.3 million). Additional SBIR Phase II contracts were awarded by the Naval Air Warfare Center for research and development ($1.299 million) and by the Office of Naval Research for research initiatives ($1.999 million). Innovital has also successfully completed multiple SBIR Phase I efforts through the Defense Health Agency, Naval Air Warfare Center, and Office of Naval Research, each valued around $240,000 to $250,000, and secured a contract from NASA's Shared Services Center for a novel surface velocity sensor ($124,942). Beyond SBIR initiatives, the company has received firm fixed-price purchase orders from the Department of Defense's Land and Maritime division for adjustable chocks and resilient utility mounts totaling approximately $160,000, and a cost-plus-fixed-fee delivery order modification from Naval Air Systems Command for the Proximity Fuze Verification and Assessment System ($527,248). As a small business, Innovital received total small business set-aside designations on substantially all of its SBIR and research development contracts, reflecting its qualified status as a small business contractor.

Innovital's federal grant activity demonstrates its capability in applied research and development for military medical applications. The company served as a prime grantee under a Defense Health Agency cooperative agreement for evaluation of a cricothyrotomy assist device, with the award extended through May 2025 following an organizational transfer of the U.S. Army Medical Research Acquisition Activity to the Defense Health Agency in October 2022. Additionally, Innovital participated as a subgrantee under a Henry M. Jackson Foundation prime grant award, where the company provided technical expertise to design, fabricate, and assemble a tourniquet testing fixture device in support of research conducted by Dr. Craig Goolsby at the Uniformed Services University of the Health Sciences, National Center for Disaster Medicine and Public Health. These grant efforts reflect Innovital's role in advancing medical technologies and devices that address critical gaps in military emergency medicine and field care capabilities.

Innovital Systems holds a single-award Basic Ordering Agreement (BOA) contract N0042125G0002 with the Naval Air Warfare Center, effective from October 2024 through October 2029. This indefinite delivery/indefinite quantity contract provides a framework for the procurement of biomedical engineering, product development, and research services across multiple technological domains. The BOA encompasses delivery of medical devices including next-generation nasopharyngeal airways and casualty transport pads, as well as specialized equipment such as decade resistors for aviation maintenance. The contract structure enables the Navy to issue task orders for Innovital's services in emergency care research, blast protection applications, and aerospace technologies, with the company's established SBIR track record and prior delivery of medical technologies to the Defense Health Agency informing its selection for this vehicle. The BOA complements Innovital's existing delivery order activities under Naval Air Systems Command and provides a flexible procurement mechanism for sustained collaboration on emerging biomedical and engineering research requirements.